VERAXA Biotech AG (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
This patent expansion is significant for VERAXA as it seeks to establish a competitive moat in the highly competitive oncology space. By securing intellectual property protection for its BiTAC technology and related innovations, the company aims to deter competitors and create barriers to entry. The patents cover key aspects of its bispecific T-cell engager and antibody-drug conjugate platforms, which are designed to address limitations of existing cancer therapies, such as off-target toxicity and limited efficacy.
For investors, the strengthened patent portfolio could enhance VERAXA's valuation and licensing potential. The company's focus on next-generation platforms positions it to potentially capture market share in the growing precision oncology market. However, the success of these technologies will ultimately depend on clinical trial outcomes and regulatory approvals.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
For more information, visit the company's newsroom at http://ibn.fm/VRXA. The full press release is available at https://ibn.fm/BqhFS.
